Why the study?
Does andexanet alfa reverse heparin after cardiopulmonary bypass?
Does andexanet alfa reverse heparin after cardiopulmonary bypass?
Andexanet alfa may serve as an effective alternative for heparin reversal after cardiopulmonary bypass in patients who cannot receive protamine.
Answers are grounded in this paper and cite their sources.
May offer alternative heparin reversal after CPB when protamine contraindicated; hypothesis-generating single case requiring prospective trials.
Heparin is the primary anticoagulant used for cardiopulmonary bypass and requires reversal to prevent postoperative bleeding. Protamine sulfate is the only United States Food and Drug Administration-approved heparin reversal agent and therefore is routinely used after cardiopulmonary bypass. Severe intraoperative protamine reactions are infrequent but may preclude full heparin reversal. Andexanet alfa has demonstrated effective in vitro heparin reversal, but clinical use has not been reported. We review the preclinical data on andexanet alfa as a heparin reversal agent and report a clinical case of andexanet alfa infusion, with complete laboratory and clinical evidence of heparin reversal.
No takes yet. Share an insight, caveat, or question.
Niehaus et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: